Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Butylene Glycols | 9 | 2006 | 14 | 1.710 |
Why?
|
| Hydroxybutyrates | 4 | 2006 | 9 | 0.810 |
Why?
|
| Pyrazoles | 4 | 2004 | 111 | 0.800 |
Why?
|
| 4-Butyrolactone | 3 | 2006 | 5 | 0.710 |
Why?
|
| Antidotes | 3 | 2004 | 27 | 0.630 |
Why?
|
| Sodium Oxybate | 5 | 2006 | 11 | 0.610 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2006 | 168 | 0.300 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2006 | 8 | 0.270 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2006 | 40 | 0.260 |
Why?
|
| Behavior, Animal | 1 | 2006 | 178 | 0.240 |
Why?
|
| Alcohol-Induced Disorders, Nervous System | 1 | 2004 | 4 | 0.230 |
Why?
|
| Substance Abuse Detection | 1 | 2005 | 90 | 0.230 |
Why?
|
| Seizures | 2 | 2006 | 196 | 0.210 |
Why?
|
| Enzyme Inhibitors | 2 | 2002 | 377 | 0.210 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2002 | 65 | 0.190 |
Why?
|
| Ethanol | 1 | 2004 | 336 | 0.190 |
Why?
|
| Fentanyl | 1 | 2022 | 36 | 0.190 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2000 | 9 | 0.180 |
Why?
|
| Ipecac | 1 | 2000 | 1 | 0.170 |
Why?
|
| Emetics | 1 | 2000 | 2 | 0.170 |
Why?
|
| Animals | 10 | 2006 | 13124 | 0.160 |
Why?
|
| Substance-Related Disorders | 2 | 2005 | 611 | 0.160 |
Why?
|
| Biotransformation | 3 | 2004 | 84 | 0.160 |
Why?
|
| Mice | 7 | 2006 | 5687 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 575 | 0.130 |
Why?
|
| Rats, Inbred Strains | 2 | 2006 | 197 | 0.130 |
Why?
|
| Rotarod Performance Test | 2 | 2004 | 6 | 0.120 |
Why?
|
| Alcohol Dehydrogenase | 2 | 2005 | 37 | 0.110 |
Why?
|
| Reflex | 2 | 2004 | 31 | 0.110 |
Why?
|
| Drug Overdose | 3 | 2005 | 159 | 0.110 |
Why?
|
| Postural Balance | 2 | 2004 | 58 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2006 | 1585 | 0.100 |
Why?
|
| Emergency Medical Services | 2 | 2005 | 110 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2005 | 1372 | 0.100 |
Why?
|
| Male | 9 | 2006 | 25910 | 0.090 |
Why?
|
| Rats | 3 | 2006 | 3292 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2005 | 1436 | 0.090 |
Why?
|
| GABA-B Receptor Antagonists | 2 | 2005 | 4 | 0.080 |
Why?
|
| Morpholines | 2 | 2005 | 66 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2022 | 2378 | 0.070 |
Why?
|
| Glutarates | 1 | 2006 | 6 | 0.070 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2006 | 13 | 0.060 |
Why?
|
| Rats, Wistar | 1 | 2006 | 224 | 0.060 |
Why?
|
| Resuscitation | 1 | 2005 | 74 | 0.060 |
Why?
|
| Chromatography, Gas | 1 | 2005 | 15 | 0.060 |
Why?
|
| Piperazines | 1 | 2005 | 119 | 0.060 |
Why?
|
| Motor Skills | 1 | 2004 | 25 | 0.060 |
Why?
|
| Placebos | 1 | 2004 | 87 | 0.060 |
Why?
|
| Reference Values | 1 | 2004 | 307 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2005 | 5285 | 0.050 |
Why?
|
| Motor Activity | 1 | 2004 | 225 | 0.050 |
Why?
|
| Bromides | 1 | 2002 | 2 | 0.050 |
Why?
|
| Posture | 1 | 2002 | 65 | 0.050 |
Why?
|
| Physostigmine | 1 | 2001 | 3 | 0.050 |
Why?
|
| Emergencies | 1 | 2001 | 79 | 0.050 |
Why?
|
| Lorazepam | 1 | 2000 | 12 | 0.050 |
Why?
|
| Dextromethorphan | 1 | 2001 | 16 | 0.050 |
Why?
|
| Child | 3 | 2022 | 6910 | 0.040 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2001 | 37 | 0.040 |
Why?
|
| Charcoal | 1 | 2000 | 5 | 0.040 |
Why?
|
| Gastric Lavage | 1 | 2000 | 5 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2022 | 413 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2000 | 395 | 0.040 |
Why?
|
| Female | 3 | 2022 | 27086 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2002 | 449 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 484 | 0.040 |
Why?
|
| Acetaminophen | 1 | 2000 | 276 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2000 | 573 | 0.030 |
Why?
|
| Humans | 6 | 2022 | 50509 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2022 | 6263 | 0.020 |
Why?
|
| Adolescent | 1 | 2000 | 6447 | 0.020 |
Why?
|
| Succinate-Semialdehyde Dehydrogenase | 1 | 2006 | 3 | 0.020 |
Why?
|
| Papio | 1 | 2006 | 16 | 0.020 |
Why?
|
| Mammals | 1 | 2006 | 50 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2006 | 88 | 0.020 |
Why?
|
| Random Allocation | 1 | 2005 | 289 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 623 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 661 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2006 | 844 | 0.010 |
Why?
|
| Pneumonia, Aspiration | 1 | 2002 | 12 | 0.010 |
Why?
|
| Hospital Administration | 1 | 2002 | 12 | 0.010 |
Why?
|
| Coma | 1 | 2002 | 16 | 0.010 |
Why?
|
| Organizational Policy | 1 | 2002 | 39 | 0.010 |
Why?
|
| Epilepsy | 1 | 2002 | 180 | 0.010 |
Why?
|
| Hospitalization | 1 | 2002 | 675 | 0.010 |
Why?
|
| Risk Factors | 1 | 2001 | 3724 | 0.010 |
Why?
|